TOP TEN perturbations for 152_f_at (Homo sapiens)

Organism: Homo sapiens
Gene: 152_f_at
Selected probe(set): 207046_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 152_f_at (207046_at) across 6673 perturbations tested by GENEVESTIGATOR:

dengue fever study 10 (DHF) / normal naive CD8 T cell sample

Relative Expression (log2-ratio):3.2222147
Number of Samples:2 / 5
Experimental dengue fever study 10 (DHF)
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis.
Control normal naive CD8 T cell sample
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.

colchicine study 7 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):3.1377726
Number of Samples:2 / 2
Experimental colchicine study 7 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.9888105
Number of Samples:4 / 4
Experimental cicloheximide study 1
MCF7 breast cancer cells were treated for 1h with cicloheximide (10 ug/ml) before vehicle treatment (0.1% ethanol) for 24h. ATC code:---
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

sulindac study 4 (3000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.9524841
Number of Samples:2 / 2
Experimental sulindac study 4 (3000uM)
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

estradiol; cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.940959
Number of Samples:4 / 4
Experimental estradiol; cicloheximide study 1
MCF7 breast cancer cells were treated with cicloheximide (10 ug/ml) for 1 hour before hormonal treatment with 17{beta}-estradiol (E2, 25 nM) for 24 hours. ATC code:
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

theophylline study 5 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.9280481
Number of Samples:2 / 2
Experimental theophylline study 5 (10000uM)
Hepatocytes treated with compound: theophylline (10000uM; CHEMBL190) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

colchicine study 6 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.8822727
Number of Samples:2 / 2
Experimental colchicine study 6 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

NGFR depletion study 1 / normal SW-480 cell sample

Relative Expression (log2-ratio):2.386445
Number of Samples:6 / 3
Experimental NGFR depletion study 1
RNAi-mediated gene knockdown of NGFR in colorectal cancer cell line SW-480.
Control normal SW-480 cell sample
Non-transduced SW-480 colorectal cell line sample.

sulindac study 5 (3000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.2171383
Number of Samples:2 / 2
Experimental sulindac study 5 (3000uM)
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):2.1974869
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.

Organism: Homo sapiens
Gene: 152_f_at
Selected probe(set): 207046_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 152_f_at (207046_at) across 6673 perturbations tested by GENEVESTIGATOR:

dengue fever study 10 (DHF) / normal naive CD8 T cell sample

Relative Expression (log2-ratio):3.2222147
Number of Samples:2 / 5
Experimental dengue fever study 10 (DHF)
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis.
Control normal naive CD8 T cell sample
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.

colchicine study 7 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):3.1377726
Number of Samples:2 / 2
Experimental colchicine study 7 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.9888105
Number of Samples:4 / 4
Experimental cicloheximide study 1
MCF7 breast cancer cells were treated for 1h with cicloheximide (10 ug/ml) before vehicle treatment (0.1% ethanol) for 24h. ATC code:---
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

sulindac study 4 (3000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.9524841
Number of Samples:2 / 2
Experimental sulindac study 4 (3000uM)
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

estradiol; cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.940959
Number of Samples:4 / 4
Experimental estradiol; cicloheximide study 1
MCF7 breast cancer cells were treated with cicloheximide (10 ug/ml) for 1 hour before hormonal treatment with 17{beta}-estradiol (E2, 25 nM) for 24 hours. ATC code:
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

theophylline study 5 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.9280481
Number of Samples:2 / 2
Experimental theophylline study 5 (10000uM)
Hepatocytes treated with compound: theophylline (10000uM; CHEMBL190) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

colchicine study 6 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.8822727
Number of Samples:2 / 2
Experimental colchicine study 6 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

NGFR depletion study 1 / normal SW-480 cell sample

Relative Expression (log2-ratio):2.386445
Number of Samples:6 / 3
Experimental NGFR depletion study 1
RNAi-mediated gene knockdown of NGFR in colorectal cancer cell line SW-480.
Control normal SW-480 cell sample
Non-transduced SW-480 colorectal cell line sample.

sulindac study 5 (3000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.2171383
Number of Samples:2 / 2
Experimental sulindac study 5 (3000uM)
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):2.1974869
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.